Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 11, 2003 - Issue 2
Submit an article Journal homepage
31
Views
8
CrossRef citations to date
0
Altmetric
Research Article

Methotrexate in inflammatory eye disease

Richard J Stawell Ocular Immunology Clinic Royal Victorian Eye Ear Hospital Melbourne, Australia
Pages 79-82 | Published online: 08 Jul 2009

References

  • Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res. 2002;4:266–273.
  • Segal R, Mozes E, Yaron M, Tartakovsky B. The effects of methotrexate on the production and activity of interleukin-L Arthritis Rheum. 1989;32:37o–377.
  • Constantin A, Loubet-Lescoulie P, Lambert N, Yassine-Diab B, Abbal M, Mazieres B, de Preval C, Cantagrel A. Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: evidence of increased interleukin-4 and interleukin-I o gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reaction. Arthritis Rheum. 1998;41:48–57.
  • Kremer JM. The mechanism of action of methotrexate in rheumatoid arthritis: The search continues. J Rheumatol. 1994;21:1-5.
  • Farber S, Diamond LK, Mercer RD, et al. Temporary remissions in acute leukaemia in children produced by folic antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med. 1948;238:787–793.
  • Gubner R, August S, Ginsberg V. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med ScL 1951;221:176–182.
  • Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985;312: 818–822.
  • Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis — results of the U.S.A.—U.S.S.R. double-blind, placebo-controlled trial. N Engl J Med. 1992;326: 1043–1049.
  • Andersen PA, West SG, O'Dell JR, Via CS, Claypool RG, Kotzin BL. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in randomized, double-blind study. Annals of Internal Medicine. 1985;103:489–496.
  • Weinblatt ME, Maier AL, Fraser PA, Coblyn JS. Longterm prospective study of methotrexate in rheumatoid arthritis: Conclusion after 132 months of therapy. J Rheumatol. 1998;25:238–242.
  • Weinblatt ME, Weissman BN, Holdsworth DE, et al. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis: 84-month update. Arthritis Rheum. 1992;35:129–137.
  • Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate: Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Guth Invest. 1993;92: 2675–2682.
  • Morgan SL, Baggott JE, Vaughn WH, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 1990;33:9–18.
  • Wong VG, Hersh EM. Methotrexate in the therapy of cyclitis. Trans Am Acad Ophthalmol Otolaryngol. 1965;69:279–293.
  • Shar SS, Lowder CY, Schmitt MA, et al. Low dose methotrexate therapy for ocular inflammatory disease. Ophthalmol. 1992;99: 1419–1423.
  • Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate for chronic noninfectious uveitis: Analysis of a case series of 160 patients. Ophthalmol. 2001;108:1134–1139.
  • Bom S, Zamiri P, Lightman S. Use of methotrexate in the management of sight-threatening uveitis. Ocular Immunology & Inflammation. 2001; 9:35–40.
  • Messmer EM, Foster CS. Destructive corneal and scleral disease associated with rheumatoid arthritis. Cornea. 1995;14:408–417.
  • Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immusuppressive drugs in patients with ocular inflammatory disorders: Recommendations of an expert panel. Am J Ophthalmol. 2000;130: 492–513.
  • Kremer JM, Alarcon GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis: Suggested guidelines for monitoring liver toxicity. Arthritis Rheum. 1994;37: 316–328.
  • Armaly MF. Effects of corticosteroids on intraocular pressure and fluid dynamics. The effects of dexamethasone in the normal eye. Arch Ophthalmol. 1963;70:482–484.
  • Becker B. Intraocular pressure response to topical corticosteroids. Invest Ophthalmol Vis Sci. 1965;4: 198–200.
  • Loewenfeld IE, Thompson HS. Fuchs' heterochromic cyclitis: A critical review of the literature. Surv Ophthalmol. 1973;17:394–457.
  • Liesegang TJ. Clinical features and prognosis in Fuchs' uveitis syndrome. Arch Ophthalmol. 1982;100:1622–1626.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.